louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05431868: Objective and Subjective Outcomes of a Trifocal IOL in Eyes With Different AL
Official title: Presbyopia-correcting Performance and Subjective Outcomes of a Trifocal Intraocular Lens in Eyes With Different Axial Lengths: a Prospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cataract
Presbyopia
Lenses, Intraocular
Myopia
Satisfaction
Keywords: Cataract
Presbyopia
Intraocular Lens
Axial Length
Satisfaction
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2022-06-24
Enrollment: 61
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This prospective cohort study collected data of patients who underwent bilateral or unilateral cataract surgery with the AT LISA tri 839MP implantation at the Department of Ophthalmology, Peking University Third Hospital, Beijing, China.

Brief summary: This prospective cohort study enrolled patients with implantation of a trifocal IOL. Only one eye of each patient was enrolled. Eyes were devided into three groups according the axial length (AL), including the short AL group, the control group and the long AL group. Manifest refraction, uncorrected and distance-corrected visual acuity at different distances, contrast sensitivity, aberrations and IOL decentration were measured three months after surgery. Spectacle independence, adverse photic phenomena, overall satisfaction and life quality were assessed with a questionnaire.


Eligibility criteria: Inclusion Criteria:

* Inclusion criteria were patients older than 40 years with significant bilateral or unilateral cataract seeking spectacle independence, with the AL between 21.00 to 30.00 mm, the prediction of postoperative corneal astigmatism less than 1.0 diopters (D), the angle kappa less than 0.50 mm, the corneal spherical aberration less than 0.5 μm and the corneal higher order aberration less than 0.5 μm.

Exclusion Criteria:

* Exclusion criteria were eyes with serious intraoperative complications, irregular corneal astigmatism, corneal scarring, uveitis, glaucoma, pseudoexfoliation syndrome, macular degeneration or other retinal impairment, amblyopia or patients having difficulties with examinations or 3 months' follow-up.

Primary outcomes:
measure: Refractive Outcomes
timeFrame: Three months after surgery.
measure: Visual Acuity at Different Distances
timeFrame: Three months after surgery.
measure: Defocus Curve
timeFrame: Three months after surgery.
measure: Contrast Sensitivity and Aberrations
timeFrame: Three months after surgery.
measure: IOL decentration
timeFrame: Three months after surgery.
measure: Subjective Satisfaction
timeFrame: Three months after surgery.
measure: Life Quality
timeFrame: Three months after surgery.
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Third Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT05589168: 911 Nurse Triage Line
Official title: 911 Nurse Triage Line Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Emergencies
Lead sponsor: The Lab @ DC
Sponsor class: OTHER_GOV
First posted: 2022-10-21
Enrollment: 6053
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Each year, millions of Americans call 911 for time-sensitive issues that don't require Emergency Medical Services (EMS). In need of medical help, these callers may treat 911 as an entry point into the healthcare system, yet an ambulance to the emergency department can harm both their own long-term health and the health of others. In a field experiment in Washington, DC, the investigators randomly assign nurses directly into 911 calls in order to triage low-acuity calls. While other 911 reforms have denied callers access to alternative resources, this effort reforms 911 by offering appropriate care.


Eligibility criteria: Inclusion Criteria:

* Low-acuity call

Exclusion Criteria:

* Incarcerated

Primary outcomes:
measure: Ambulance dispatch
timeFrame: During or immediately subsequent to call
measure: Ambulance transport
timeFrame: During or immediately subsequent to call
measure: ED visit, 24 hours
timeFrame: 24 hours
measure: ED visit, 6 months
timeFrame: 6 months
measure: Primary care visit, 24 hours
timeFrame: 24 hours
measure: Primary care visit, 6 months
timeFrame: 6 months
measure: 911 use, 24 hours
timeFrame: 24 hours
measure: 911 use, 6 months
timeFrame: 6 months
measure: Health expenditures
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Washington
country: United States
facility: Office of Unified Communications
state: District of Columbia
Study officials:
References:
Clinical trial NCT02317068: Increasing Atrial Base Rate Pacing to Reduce Atrial Fibrillation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Sick Sinus Syndrome
Paroxysmal Atrial Fibrillation
Keywords: sick sinus syndrome
paroxysmal atrial fibrillation
atrial pacing
high atrial base rate pacing
Lead sponsor: Urmia University of Medical Sciences
Sponsor class: OTHER
First posted: 2014-12-15
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study aims to determine whether increasing atrial base rate pacing to achieve at least 75-80% atrial pacing in patients with sick sinus syndrome undergoing the implementation of dual-chamber pacemaker can be useful to prevent or decrease the atrial fibrillation during 6 months follow-up duration.


Eligibility criteria: Inclusion Criteria:

* Sick sinus syndrome patients having dual-chamber pacemaker
* Having paroxysmal AF defined as at least 2 episodes of AHR/AMS \>190 b/min lasting \>6 minutes
* Having normal atrioventricular conduction

Exclusion Criteria:

* Other clinical indications for pacing except sick sinus syndrome (bradycardia-tachycardia syndrome)
* History of acute coronary syndrome
* Significant heart valve disease
* Chronic AF before randomization
* Overt heart failure
* Malignancy
* Any reasons for antiarrhythmic medication use
* Inability to follow patients every 3 months

Primary outcomes:
measure: Atrial high rate/Automatic mode switch episodes
timeFrame: During 6 Months
Secondary outcomes:
measure: Stroke
timeFrame: During 6 months
measure: Myocardial infarction
timeFrame: During 6 months
measure: Heart failure
timeFrame: During 6 months
measure: Worsening Functional Class
timeFrame: During 6 months
measure: Death
timeFrame: During 6 months
Other outcomes:
Locations:
city: Urmia
country: Iran, Islamic Republic of
facility: Seyyed-al-Shohada Heart Center, UMSU
state: West-Azerbaijan
Study officials:
References:
Clinical trial NCT02202668: Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers
Official title: Transcutaneous Raman Spectroscope Analyses of Diabetic Foot Ulcers
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Diabetic Foot Ulcer
Keywords: Foot ulcer, diabetic
Spectrum analysis, Raman
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2014-07-29
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: The primary translational research objective of the study is to demonstrate feasibility of using the Transcutaneous Raman Spectroscopy technology in a point-of-care environment. This study represents an initial evaluation of the device in a small cohort of human patients with diabetic foot ulcers. We will be evaluating safety, device design and certain human engineering factors associated with point of care use of the TRS. We anticipate the data we collect in this study will form the basis of later medical device studies.


Eligibility criteria: Inclusion Criteria:

* Ability to provide informed consent
* Diagnosis of diabetes mellitus
* Full thickness or superficial foot and ankle ulcers based on clinical assessment (e.g., University of Texas (UT) grades 1-3, stages A-D). For reference, see Appendix 1 for the UT classification table

Exclusion Criteria:

* Age less than 18 or greater than 80 years old
* Subject has a psychological or sociological condition or an addictive disorder that would preclude informed consent
* Completely epithelialized ulcer based on clinical assessment with no ischemia or infection (UT classification 0A)
* Current or previous use of anti-resorptive bisphosphonate drugs (e.g., risedronate (Actonel) and alendronate (Fosamax))

Primary outcomes:
measure: Transcutaneous Raman spectra of subcutaneous deep wound soft tissue and underlying bone
timeFrame: Baseline, then monthly for 3 months
Secondary outcomes:
measure: Wound temperature post-Transcutaneous Raman Spectroscope
timeFrame: Baseline then monthly for 3 months
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Blake Roessler, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02752568: Assisted Hatching Versus Endometrial Scratch in Recurrent Implantation Failure
Official title: Assisted Hatching Versus Endometrial Scratch in Recurrent Implantation Failure.A Comparative Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Recurrent Implantation Failure
Lead sponsor: Kasr El Aini Hospital
Sponsor class: OTHER
First posted: 2016-04-27
Enrollment: 300
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: 300 recurrent implantation failure patients will be alternatively assigned to assisted hatching , endometrial scratch , and no treatment ,100 patients in each group

Detailed description: Group 1 consists of 100 patients will undergo endometrial scratch followed by controlled ovarian hyperstimulation Group 2 consists of 100 patients will undergo controlled ovarian hyperstimulation\& assisted hatching Group 3 consists of 100 patients will undergo controlled ovarian hyperstimulation

Eligibility criteria: Inclusion Criteria:

* recurrent implantation failure
* normal uterine cavity by transvaginal ultrasound

Exclusion Criteria:

* endometrial polyp or fibroid distorting the endometrium
* hydrosalpinx
* preimplantation genetic diagnosis
* severe male factor

Primary outcomes:
measure: number of patients with positive pregnancy test
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: kasrelaini hospital
name: suzy abdelaziz, lecturer
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lacey L, Hassan S, Franik S, Seif MW, Akhtar MA. Assisted hatching on assisted conception (in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI)). Cochrane Database Syst Rev. 2021 Mar 17;3(3):CD001894. doi: 10.1002/14651858.CD001894.pub6.
Clinical trial NCT05095168: Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects
Official title: Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: PNH
Lead sponsor: CANbridge Life Sciences Ltd.
Sponsor class: INDUSTRY
First posted: 2021-10-27
Enrollment: 31
Sex: ALL
Minimum age (years): 21
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a single site, single dose escalation study in healthy subject with CAN106. The study is to assess the safety and tolerability of single escalating doses of CAN106; to characterize the PK and PD profile of CAN106; and to evaluate the immunogenicity of CAN106 injection.


Eligibility criteria: Inclusion Criteria:

* Subjects must be able to understand and provide informed consent.
* Males or females, between 21 and 45 years of age, inclusive;
* Body mass index must be within the range of 18.5 to 32.0 kg/m2;
* 12-lead electrocardiogram (ECG) within normal limits with no clinically significant abnormalities in the opinion of the Investigator；
* Systolic blood pressure ≤140 mmHg and a diastolic blood pressure of ≤ 90 mmHg after 5 minutes with supine rest；
* non-pregnancy
* meningococcal vaccinations for at least 2 weeks before dosing

Exclusion Criteria:

* Disease or conditions interfere with participating the trial
* Active serious mental illness or psychiatric disorder
* clinically relevant abnormal test results in hepatic function
* unacceptable CBC lab test
* asymptomatic complement deficiency
* Any other clinical safety laboratory test
* HIV, HBV, HCV positive
* Alcohol and drug abuse
* etc.

Primary outcomes:
measure: Incidence of subjects with dose-limiting toxicity (DLTs)
timeFrame: 6-months after dosing
measure: Incidence of adverse events (AEs)
timeFrame: 6-months after dosing
measure: Incidence of severe adverse events (SAEs)
timeFrame: 6-months after dosing
Secondary outcomes:
measure: PK parameters - tmax
timeFrame: 6-months after dosing
measure: PK parameters-Cmax
timeFrame: 6-months after dosing
measure: PK parameters - AUC0-t
timeFrame: 6-months after dosing
measure: PK parameters - t1/2
timeFrame: 6-months after dosing
measure: PD endpoints-free C5
timeFrame: 6-months after dosing
measure: PD endpoints-CH50
timeFrame: 6-months after dosing
measure: PD endpoints-total C5
timeFrame: 6-months after dosing
measure: Immunogenicity
timeFrame: 6-months after dosing
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: National University Hospital
Study officials:
References:
Clinical trial NCT04442568: Impact of ERAS in LSG
Official title: Enhanced Recovery After Surgery Protocol in Laparoscopic Sleeve Gastrectomy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Laparoscopic Sleeve Gastrectomy
Enhanced Recovery After Surgery
Pain, Postoperative
Nausea, Postoperative
Vomiting, Postoperative
Lead sponsor: Umraniye Education and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2020-06-22
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Patients
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Patients with BMI \>35 and chronic diseases or BMI \>40 will be scheduled to receive Laparoscopic Sleeve Gastrectomy (LSG). Two groups are planned according to receive Enhance recovery after surgery (ERAS) protocol or not. All participants will receive standard LSG. Participants of ERAS will receive anesthesia and post-surgical nutrition protocol which are determined for ERAS. All patients will be checked for status of pain with VAS score, nausea and vomiting with PONV score at postoperative 2nd hour, 12th hour. In ERAS group liquid oral intake will be started between postoperative 2nd and 4th hours. In no ERAS group liquid oral intake will be started in the morning of postoperative first day. The patients who provides discharge criterias will be discahrged. these criterias are; To provide adequate pain relief with paracetamol and nonsteroidal painkillers, No wound problem, No complications after surgery, Pulse rate \<90 beats / min, temperature ≤ 37 · 5 ° C, respiratory rate, \<20 breaths / minute, To be able to mobilize easily, To be able to drink 1 liter of water after surgery.

Emergency admissions of the participants within a month after surgery will be recorded.


Eligibility criteria: Inclusion Criteria:

* must be performed laparoscopic sleeve gastrectomy
* body mass index \> 35 with a comorbidıty or ,body mass index \> 40

Exclusion Criteria:

* surgery with peroperative complication
* revision surgery applications

Primary outcomes:
measure: length of hospital stay
timeFrame: till discharge, an average of 36 hours
measure: number of emergency re-admission after surgery
timeFrame: during postoperative first 30 days
measure: Score of Visual analog scale
timeFrame: postoperative 24 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05089968: Ventilation Associated Pneumonia and Covid-19
Official title: Ventilator-associated Pneumonia Ecology Comparison in a French ICU Center NIMES Between First and Second Wave of COVID-19 : a Retrospective Monocentric Descriptive Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: SARS-CoV2 Infection
Ventilator Associated Pneumonia
Ards
COVID-19
Keywords: Intensive care Unit
multidrug resistance
COVID 19 ARDS
ventilator associated pneumonia
SARS-CoV2 Infection
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2021-10-22
Enrollment: 268
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients over 18 years old with a SARS-CoV-2 infection confirmed by positive PCR tests of nasopharyngeal or respiratory secretion samples. In addition, patients included presented a healthcare associated pneumonia according to SFAR(French Society of Anesthesia and Intensive Care) recommendations and based on criteria adapted from the European Centre for Disease Prevention and Control (ECDC) recommendations. Patients who refused their data use were excluded.

Brief summary: In December 2019, a new pandemic emerged, the COVID-19 disease caused by a SARS-Cov-2 virus. One of the most common symptoms of COVID-19 is mainly respiratory failure and patients requires assistance by mechanical ventilation. Ventilator-associated pneumonia (VAP) is a risk of this assistance. Since the beginning of the pandemic, Standard of care have evolved with new data. The prevalence of these VAPs seems significantly higher in the population of patients with ARDS COVID-19 (40-50%) and their ecology seems to have evolved over time, particularly in terms of bacterial resistance. Investigators want to describe and compare this evolution of bacterial and fungal ecology as well as identify potential risk factors that may be associated with these changes in ecology during different waves.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Positive SARS-Cov-2 polymerase chain reaction (PCR)
* healthcare associated pneumonia

Exclusion Criteria : Patient opposition to participate to the study

Primary outcomes:
measure: VAP ecological difference between the first and second waves of COVID
timeFrame: January 2020 to January 2021
Secondary outcomes:
measure: proportion of fungal co-infections
timeFrame: January 2020 to January 2021
measure: duration of mechanical ventilation
timeFrame: Day 28
measure: number of days of organ failure
timeFrame: Day 28
measure: Mortality
timeFrame: Day 28
measure: proportion of patients treated with corticosteroid therapy
timeFrame: Day 28
measure: probabilistic antibiotic therapy at admission
timeFrame: Day 1
measure: antiviral treatment
timeFrame: Day 28
Other outcomes:
Locations:
city: Nîmes Cedex 09
country: France
facility: CHU de Nîmes - Hôpital Universitaire Carémeau
Study officials:
affiliation: Centre Hospitalier Universitaire de Nîmes
name: Claire ROGER, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06969768: Proteogenomics for Follicular Cell-derived Thyroid Cancer: Development of a Classification and Prognosis Prediction Model
Official title: Integrative Multi-Omics Refines the Molecular Subtypes of Thyroid Cancers and Enhances Cancer-Progression Prediction
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Thyroid Cancer
Keywords: Thyroid cancer
Proteogenomics
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: Korea Health Industry Development Institute
name: National Research Foundation of Korea
First posted: 2025-05-14
Enrollment: 275
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients diagnosed with thyroid cancer

Brief summary: This study aims to refine the molecular classification of thyroid cancer (TC) using a multi-omics approach. By identifying a novel gene set and applying decision-tree modeling, the study seeks to improve diagnostic accuracy and predict tumor progression in BRAFV600E-like and RAS-like TC subtypes. Protein biomarkers were validated via immunohistochemistry (IHC), with findings confirmed across external datasets.


Eligibility criteria: Inclusion Criteria:

* Patients with a confirmed clinical diagnosis of thyroid cancer
* Availability of surgically resected thyroid tissue suitable for omics analysis

Exclusion Criteria:

- Patients who have received chemotherapy for other malignancies

Primary outcomes:
measure: Classification Accuracy of Gene-Based Model
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References: